Market revenue in 2023 | USD 19.3 million |
Market revenue in 2030 | USD 123.5 million |
Growth rate | 30.3% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Diagnostics |
Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.87% in 2023. Horizon Databook has segmented the UK peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is one of the major peptide drug conjugates markets in Europe. Regional players are engaged in developing effective & economical treatment therapeutics to address the increasing prevalence and growing need for therapeutics, fueling market growth in the country.
Major players are investing in pharma R&D to develop novel therapeutics, which is expected to fuel market growth in the country. Favorable government initiatives and increased R&D activities in the country are driving market growth.
In addition, the high disease burden and significant government efforts in spreading awareness regarding various target diseases are driving the market. Moreover, the presence of an established healthcare system, high disposable income, a rise in awareness levels about early diagnosis of diseases, and an increasing incidence of antibiotic-resistant infections are expected to further drive the market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the UK peptide drug conjugates market , including forecasts for subscribers. This country databook contains high-level insights into UK peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account